These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11309325)

  • 21. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
    Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
    J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.
    Ross RW; Manola J; Hennessy K; Galsky M; Scher H; Small E; Kelly WK; Kantoff PW
    Clin Cancer Res; 2005 Jul; 11(14):5195-8. PubMed ID: 16033836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib.
    Mathew P; Tannir N; Tu SM; Wen S; Guo CC; Marcott V; Bekele BN; Pagliaro L
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):889-96. PubMed ID: 21290244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
    George D
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
    Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
    Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;
    Urol Oncol; 2005; 23(1):1-7. PubMed ID: 15885575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
    Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Krüger EA; Gubish E; Pluda JM; Reed E
    Clin Cancer Res; 2001 Jul; 7(7):1888-93. PubMed ID: 11448901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer.
    Friedlander TW; Weinberg VK; Huang Y; Mi JT; Formaker CG; Small EJ; Harzstark AL; Lin AM; Fong L; Ryan CJ
    Oncol Rep; 2012 Jan; 27(1):3-9. PubMed ID: 21971890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
    Small EJ; Fontana J; Tannir N; DiPaola RS; Wilding G; Rubin M; Iacona RB; Kabbinavar FF
    BJU Int; 2007 Oct; 100(4):765-9. PubMed ID: 17822457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
    Eckhardt SG; Rizzo J; Sweeney KR; Cropp G; Baker SD; Kraynak MA; Kuhn JG; Villalona-Calero MA; Hammond L; Weiss G; Thurman A; Smith L; Drengler R; Eckardt JR; Moczygemba J; Hannah AL; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 1999 Apr; 17(4):1095-104. PubMed ID: 10561166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK).
    Jungi WF; Bernhard J; Hürny C; Schmitz SF; Hanselmann S; Gusset H; Pestalozzi D; Goldhirsch A
    Support Care Cancer; 1998 Sep; 6(5):462-8. PubMed ID: 9773464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weekly chemotherapeutic regimen in metastatic prostate cancer.
    Burk K
    Prog Clin Biol Res; 1989; 303():261-75. PubMed ID: 2674989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
    Carducci MA; Padley RJ; Breul J; Vogelzang NJ; Zonnenberg BA; Daliani DD; Schulman CC; Nabulsi AA; Humerickhouse RA; Weinberg MA; Schmitt JL; Nelson JB
    J Clin Oncol; 2003 Feb; 21(4):679-89. PubMed ID: 12586806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of CI-958 in patients with hormone-refractory prostate cancer.
    Woolley PV; Freiha FS; Smith DC; Carlson L; Hofacker J; Quinn N; Grove W; Trump DL
    Cancer Chemother Pharmacol; 1999; 44(6):511-7. PubMed ID: 10550573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
    Heath EI; Hillman DW; Vaishampayan U; Sheng S; Sarkar F; Harper F; Gaskins M; Pitot HC; Tan W; Ivy SP; Pili R; Carducci MA; Erlichman C; Liu G
    Clin Cancer Res; 2008 Dec; 14(23):7940-6. PubMed ID: 19047126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer.
    Mathew P; Thall PF; Wen S; Bucana C; Jones D; Horne E; Oh WK; Morris MJ; Lee YC; Logothetis CJ; Lin SH; Fidler IJ
    Br J Cancer; 2008 Nov; 99(9):1426-32. PubMed ID: 18841158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.
    Scher HI; Curley T; Geller N; Engstrom C; Dershaw DD; Lin SY; Fitzpatrick K; Nisselbaum J; Schwartz M; Bezirdjian L
    J Clin Oncol; 1990 Nov; 8(11):1830-8. PubMed ID: 1700078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suramin treatment in hormone- and chemotherapy-refractory prostate cancer.
    Garcia-Schürmann JM; Schulze H; Haupt G; Pastor J; Allolio B; Senge T
    Urology; 1999 Mar; 53(3):535-41. PubMed ID: 10096380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.